248 results about "Transfer vector" patented technology

This invention relates to a system for introducing nucleic acid into the DNA of a cell. The system includes the use of a member of the SB family of transposases (SB) or nucleic acid encoding the transposase and a nucleic acid fragment that includes a nucleic acid sequence with flanking inverted repeats. The transposase recognizes at least a portion of an inverted repeats and incorporates the nucleic acid sequence into the DNA. Methods for use of this system are discussed.

The present invention provides for transposon vectors encoding expression control region-traps and gene-traps. Also provided are dicistronic vectors. Certain embodiments of the invention contain internal ribosome entry sites.

Recombinant lentiviruses and transfer vectors for transgene delivery as well as methods for gene therapy using such vectors are disclosed. The invention provides a third generation lentiviral packaging system and a set of vectors for producing recombinant lentiviruses, as well as novel tissue specific enhancer and promoter elements useful for optimizing liver specific transgene delivery. The transgene is preferably a blood clotting factor such as human factor IX (hFIX) or human factor VIII (hFVIII) and can be used for treatment of hemophilia.

The present invention relates to nucleic acid sequences coding for modified coagulation factors, preferably coagulation factor VIII, and their derivatives; recombinant expression vectors containing such nucleic acid sequences; host cells transformed with such recombinant expression vectors; and recombinant polypeptides and derivatives coded for by said nucleic acid sequences, whereby said recombinant polypeptides and derivatives have biological activities and prolonged in vivo half-lives compared to the unmodified wild-type proteins. The invention also relates to corresponding sequences that result in improved in vitro stability. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such nucleic acid sequences.

The present invention relates to modified cDNA sequences coding for human Factor X and their derivatives with improved stability and modified activation sequences, recombinant expression vectors containing such cDNA sequences, and host cells transformed with such recombinant expression vectors. The invention also relates to recombinant factor X polypeptides and derivatives which have biological activities of the unmodified wild type protein but with improved stability and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA.

The invention discloses porcine circovirus II-type recombinant baculovirus as well as a preparation method and application thereof. ORF2 gene is artificially synthesized by referring to a PCV2b isolated strain ORF2 gene sequence; the synthesized ORF2 gene is connected to pFBDPHmHNM1P10eGFP plasmid by adopting the plasmid as a framework vector, so that a baculovirus transfer vector pFBDPHm 30RF2 is obtained. The baculovirus transfer vector pFBDPHm30RF2 is mixed with DH10Bac escherichia coli competent cells, and the positive bacterial colony is selected to obtain a recombinant rod granule rBac-PVR30RF2; the rod granule is transferred with a sf9 cell to obtain the recombinant baculovirus QP-Ac-30RF2. The recombinant baculovirus can be used for efficiently expressing the PCV20RF2 protein and forming virus-like particles. The VLP which is expressed and packaged by the recombinant baculovirus disclosed by the invention is used for preparing inactivated vaccine, and the organism is induced to generate specific immunity response after a 28-day-aged piglet is immunized, and the pig body can be completely protected from virulent attacks of the porcine circovirus.

The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and / or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding FVIII sequences that result in improved expression yield. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such modified nucleic acid sequences.

An architecture is shown where an execution unit is tightly coupled to a shared, reconfigurable memory system. Sequence control signals drive a DMA controller and address generator to control the transfer of data from the shared memory to a bus interface unit (BIU). The sequence control signals also drive a data controller and address generator which controls transfer of data from the shared memory to an execution unit interface (EUI). The EUI is connected to the execution unit operates under control of the data controller and address generator to transfer vector data to and from the shared memory. The shared memory is configured to swap memory space in between the BIU and the execution unit so as to support continuous execution and I / O. A local fast memory is coupled to the execution unit. A local address generator controls the transfer of scalar data between the local fast memory and the execution unit. The execution unit, local fast memory and local address generator form a fast memory path that is not dependent upon the slower data path between the execution unit and shared memory. The fast memory path provides for fast execution of scalar operations in the execution unit and rapid state storage and retrieval for operations in the execution unit.

Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.

The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and / or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding FVIII sequences that result in improved expression yield. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such modified nucleic acid sequences.

The invention discloses an establishing method of a bacterial artificial chromosome recombinant duck plague virus rescue system platform and application of the platform. A bacterial artificial chromosome recombinant duck plague virus is obtained by inserting a recombinant duck plague virus transfer vector pUC18 / EGFP-TKAB-BAC11 in a TK domain, wherein the recombinant duck plague virus transfer vector contains a TK gene left-right homologous arm, a reporter gene EGFP and a bacterial artificial chromosome core function component. By means of the platform, the in-vitro biologics characteristics of a UL55 gene-deleted strain established through an inside-bacterium two-step RED recombination method and a back mutation strain and parent strain of the UL55 gene-deleted strain are quite close; the functions are not related to positioning of a UL26.5 gene in a cell. The method is beneficial to development of pathogenic mechanism and gene function research of DPV CHv and is beneficial to the duck plague virus prevention and the research and application of recombinant duck plague virus vaccines of other poultry infectious diseases based on the platform; in addition, due to the fact that the recombinant virus carries a TK deletion mark and an EGFP gene, a mark vaccine can be developed to clinically distinguish a wild virus and a recombinant vaccine virus.

The invention discloses porcine O-type foot-and-mouth disease virus recombinant baculovirus as well as a preparation method and application thereof. Sequences of VP0, VP1 and VP3 genes are artificially synthesized by referring to an FMDV (Foot And Mouth Disease Virus) O-type epidemic strain gene sequence; the VP0, VP1 and VP3 genes are connected to pFBDPHmHNM1P10eGFP plasmid by adopting the plasmid as a framework vector, so that a baculovirus transfer vector pFBDPHmVP013 is obtained. The baculovirus transfer vector pFBDPHmVP013 is mixed with DH10Bac escherichia coli competent cells, and the positive bacterial colony is selected to obtain a recombinant shuttle vector Bacmid; the shuttle vetcor Bacmid is transferred with a sf9 cell, and the recombinant baculovirus QP-Ac-FVLP is obtained by collecting the cell supernatant. The recombinant baculovirus can be used for efficiently expressing FMDVVP0, Vp1 and Vp3 proteins and forming virus-like particles. And the virus-like particles are used for preparing subunit vaccine, so that the organism is induced to generate specific immunity response after the mouse is immunized.

Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.

The present invention relates to a gene transfer vector (GTV) and in particular to an integrating gene transfer vector (IGTV), which comprises at least one genetic insulator element (GIE), wherein the each comprises at least two copies of an element selected from the group consisting of: a CTF binding site; a first CTCF binding site and a second CTCF binding site, wherein the first and the second CTCF binding sites are derived from the regulatory sequences of different genes.

The invention discloses a target tracking method based on correlation of space-time-domain edge and color feature. The target tracking method based on correlation of space-time-domain edge and color feature comprises the following steps: (1) selecting a tracked target area; (2) extracting the edge outline of the target and calculating the direction angle of the edge; (3) along the two orthogonal directions of horizontal direction and vertical direction, conducting statistics of edge-color symbiosis character pairs, and building a target edge-color correlation centroid model; (4) selecting the centroids of the edge-color pairs with high confidence coefficient to conduct probability weighting, so as to gain a transfer vector of a target centroids in a current frame; (5) conducting statistics of histograms of target edge distances between adjacent frames, conducting probability weighting of the successfully matched distance change rates between the adjacent frames so as to gain a target dimension scaling parameter. By means of the target tracking method based on correlation of space-time-domain edge and color feature, a target tracking in a crowded scene, a shelter, and a condition that the target dimension changes is achieved, and robustness, accuracy and instantaneity of the tracking are improved. The target tracking method based on correlation of space-time-domain edge and color feature has a wide application prospect in the video image processing field, and can be applied to the fields such as intelligent video monitoring, enterprise production automation and intelligent robot.

The invention discloses a cat omega interferon mutant as well as a preparation method and an application thereof, and belongs to the field of preparation and application of cat omega interferons. A cat omega 2 or omega 11 interferon mutant is obtained by comparing gene sequences and amino acid sequences of 13 subtypes of cat omega interferon and performing amino acid site-directed mutation on cat omega 2 or omega 11 interferon. The invention further discloses the method for preparing the cat omega interferon mutant. The method comprises the following steps: cloning a gene for coding the cat omega 2 or omega 11 interferon mutant into a baculovirus transfer vector, recombining with a baculovirus for infecting an insect host, expressing an exogenous gene, and obtaining a cat omega interferon protein expression product. The method is simple in process, the cat omega interferon capable of being safe to use can be efficiently and stably obtained, and the antiviral activity of the cat omega interferon mutant is remarkably improved. The cat omega 2 or omega 11 interferon mutant can be used for preparing drugs or reagents for preventing or treating cat viral diseases.

Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.

An architecture is shown where an execution unit is tightly coupled to a shared, reconfigurable memory system. Sequence control signals drive a DMA controller and address generator to control the transfer of data from the shared memory to a bus interface unit (BIU). The sequence control signals also drive a data controller and address generator which controls transfer of data from the shared memory to an execution unit interface (EUI). The EUI is connected to the execution unit operates under control of the data controller and address generator to transfer vector data to and from the shared memory. The shared memory is configured to swap memory space in between the BIU and the execution unit so as to support continuous execution and I / O. A local fast memory is coupled to the execution unit. A local address generator controls the transfer of scalar data between the local fast memory and the execution unit. The execution unit, local fast memory and local address generator form a fast memory path that is not dependent upon the slower data path between the execution unit and shared memory. The fast memory path provides for fast execution of scalar operations in the execution unit and rapid state storage and retrieval for operations in the execution unit.

The invention provides a method for expressing foot-and-mouth disease antigens in insects using recombinant baculoviruses, which includes: cloning different gene combinations of foot-and-mouth disease into baculovirus delivery vectors to construct transfer vectors; using the constructed transfer vectors to transfer Infect the baculovirus and perform DNA recombination to obtain the recombinant baculovirus; infect the insect host with the recombinant baculovirus; culture the infected insect host to express the foot-and-mouth disease antigen; collect and purify the expressed foot-and-mouth disease antigen. The method of the present invention uses a baculovirus expression system to safely and efficiently produce foot-and-mouth disease antigens in a silkworm bioreactor. The prepared antigens are extremely safe and can directly produce vaccines to immunize animals. The method of preparing foot-and-mouth disease antigen of the present invention does not require investment in building a factory, has no three wastes, consumes very little energy such as electricity and water resources, and its production cost is also significantly lower than the traditional method of preparing foot-and-mouth disease antigen. It is safe, efficient, has low energy consumption and low cost. Low and many advantages.

The invention provides a method for producing porcine circovirus type II capsid protein by utilizing a silkworm bioreactor, and belongs to the field of biotechnology. In the method, by taking a bombyx nuclear polyhedrosis virus as a vector, porcine circovirus type II capsid protein genes are integrated into a polyhedrosis promoter of the bombyx nuclear polyhedrosis virus so as to express target protein by a mode of the homologous recombination of a homologous arm of the nuclear polyhedrosis virus in a transfer vector and bombyx nuclear polyhedrosis virus (BmNPV) genes; a recombinant bombyx nuclear polyhedrosis virus containing target protein genes is obtained by a plaque sieving method, and the target protein is expressed in large scale by using a bombyx bioreactor so as to prepare a subunit vaccine containing recombinant porcine circovirus type II capsid protein; and piglet infection experiments verify that the subunit vaccine has the excellent immune protective effect. The method has the characteristics of high expression efficiency, good activity of the target protein, low production cost and the like, and is suitable for large-scale production.

The invention relates to a method for screening non-essential regions for replication of a goat pox virus and universal transfer vectors for same. The method comprises the steps of amplifying two-end gene segments of any two regions of a goat pox virus gene by using a PCR (Polymerase Chain Reaction) method; then, inserting an enhanced green fluorescent protein (EGFP) gene and a xanthine-guanine phosphoribosyl transferase (gpt) gene expression cassette into the segments; establishing two universal transfer vectors of the goat pox virus; and acquiring a recombinant virus expressing an exogenous gene stably from the transfer vectors, thereby determining the selected regions to be non-essential regions for replication of the goat pox virus, wherein each universal transfer vector contains one unique restriction enzyme cutting site Sal I and allows gene expression cassettes of other items to insert in. The recombinant virus obtained by means of the two universal transfer vectors provided by the invention not only has a growth performance similar to a parent virus, but also has better safety because a plurality of toxicity related genes in a genome are knocked out in an orientation way, and has the potential to be developed into an attenuated vaccine strain for gene engineering.

A lentiviral vector system is described. The system comprises a lentiviral transfer vector and a packaging construct. The transfer vector comprises (a) a 5′ LTR; (b) a 3′ LTR comprising a polyadenylation signal; (c) a minimal packaging signal, (d) (i) at least one heterologous upstream enhancer (UE) sequences, and / or (ii) at least one additional copy of endogenous UE sequences operatively associated with said polyadenylation signal; and (e) a PRE. The packaging construct comprises a nucleic acid encoding and expressing a lentiviral Gag nucleic acid (preferably Gag and Pol). Preferably the lentiviral Gag nucleic acid is a mutated Gag nucleic acid containing one or more substitution mutations, wherein said mutated Gag nucleic acid encodes the same amino acid sequence as the corresponding unmutated Gag nucleic acid, but differs from the nucleic acid sequence of said corresponding unmutated Gag nucleic acid sequence due to the degeneracy of the genetic code. Preferably the packaging construct further comprises a heterologous nucleic acid encoding and expressing an adenovirus VA RNA. The transfer vector and packaging construct can be used together in a producer cell to produce viral particles.

The invention provides methods for treating ocular diseases using a recombinant vehicle to express a protein useful in the treatment of ocular disease, with particular preference for use of neurotrophin-4 (NT4) for targeting subpopulations of cells in the retina. A genetically engineered gene transfer vector containing sequences encoding a growth factor such as neurotrophin-4 (NT4) is used to transduce cells of the retinal ganglion cell (RGC) layer, in situ, via administration of the vector intravitreally. Accordingly, methods are disclosed for treating subjects in need thereof by therapeutic protein delivery via a recombinant expression vector, including rescue of photoreceptors by targeting the RGC layer subpopulation of retinal cells.

A transfer process in which, an original vector signal is precoded to an intermediately-precoded vector signal, and the extended modulo operation is performed when the intermediately-precoded vector signal is located outside a predetermined extended-modulo limit area, and the precoded vector signal is transferred through a system having a predetermined filtering characteristic. From the transferred vector signal, the original vector signal is detected, based on a relationship between the vector components of the original vector signal and the transferred vector signal.

The present invention relates to T-DNA vectors and methods for obtaining transgenic eukaryotes using said vectors. The transgenic eukaryotes are characterized in that they contain the T-DNA but not the illegitimately transferred vector backbone sequence. This is achieved by modifying the T-DNA borders such that they are more efficiently nicked or such that they allow elimination of illegitimately transferred vector backbone sequences by means of recombination.

The present invention provides a new class of non-viral transduction vectors that can be used for both in vivo and in vitro applications. The present invention also provides a gene transfer vector that has comparable efficiency to a viral vector without the potential for a life-threatening immune response. Complexes according to the invention or portions thereof, can comprise a cellular delivery molecule or agent that can facilitate the translocation of the complex or portion thereof into cells. In some embodiments, cellular delivery molecules for use in the present invention may comprise one or more polymers of the present invention, e.g., polyamides, dendritic macromolecules and carbohydrate-containing degradable polyesters.

The invention relates to a strippable ultra-thin transfer vector metal foil, which comprises an ultra-thin metal foil with a thickness of between 0.1 and 9 microns and a strippable transfer adhesive film, wherein the transfer adhesive film is provided with a low-viscosity adhesive layer; the ultra-thin metal foil can be attached to the strippable transfer adhesive film through the low-viscosity adhesive layer; and the other surface of the ultra-thin metal foil is covered with a protective film. A method for manufacturing the strippable ultra-thin transfer vector metal foil comprises the following steps: (1) forming a bright matrix carrier band; (2) electrodepositing a metal on the bright matrix carrier band so as to form a strippable metal foil; and (3) jointing the transfer adhesive film on the metal foil, and taking off the metal foil and transferring the metal foil to the transfer adhesive film. The strippable ultra-thin transfer vector metal foil achieves the large scale production and use of the ultra-thin metal foil with a thickness of less than 0.1 to 9 microns. Simultaneously, the strippable ultra-thin transfer vector metal foil has the advantages of simple process, high production efficiency, recyclable bright matrix carrier band, low production cost, and broad market prospect.

The invention discloses a duck plague virus transfer vector pUC-deltagC-EGFP and a duck plague virus gC-deleted recombinant strain DPV-deltagC-EGFP. An escherichia coli DH5alpha containing the transfer vector pUC-deltagC-EGFP is collected on November 30th, 2011, in China Center for Type Culture Collection at Wuhan University of China, and has a collection number of CCTCC NO:M2011432. After the transfer vector is subjected to homologous recombination with the duck plague virus, and after plaque purification, the EGFP-labeled recombinant virus DPV-deltagC-EGFP is obtained. As a result of experiments, same as an attenuated vaccine, the recombinant virus DPV-deltagC-EGFP with three dosages can provide complete protection for ducklings attacked by virulent virus. Therefore, the recombinant strain has certain potential to be developed into a novel vaccine which can effectively prevent duck plague.